Aethlon Medical Inc (AEMD) FinancialsAEMDAethlon Medical Inc

Aethlon Medical Inc (AEMD) generates its revenue primarily from Aethlon, which accounts for 100.0% of total sales, equivalent to $13.12K. Understanding this concentration is critical for investors evaluating how AEMD navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Aethlon Medical Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -160.91%, provide a clear picture of how effectively AEMD converts its operational activities into shareholder value.

In the context of the broader market, AEMD competes directly with industry leaders such as NMTC and BMRA. With a market capitalization of $10.07M, it holds a leading position in the sector. When comparing efficiency, AEMD's gross margin of N/A stands against NMTC's 59.94% and BMRA's 8.14%. Such benchmarking helps identify whether Aethlon Medical Inc is trading at a premium or discount relative to its financial performance.

Aethlon Medical has reported consistent net losses, with the latest loss for Q1 2027 at $1.55 million. The EPS has improved slightly to -4.02 from -42.43 a year prior, reflecting some operational improvements. However, the company still operates at a loss, which raises concerns about its long-term viability.